Answers are grounded in this paper and cite their sources.
Altered RNA metabolism and impaired proteostasis are central to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). STAU1 is a multifunctional RNA-binding protein that regulates mRNA decay and trafficking, interacts with ATXN2, and is overabundant in neurodegenerative disease models. STAU1 overabundance activates mTOR signaling, impairs autophagy and stress-granule turnover, and thereby participates in a feed-forward circuit that further elevates STAU1 abundance. Here, we tested whether genetic and antisense oligonucleotide (ASO)-mediated STAU1 lowering can interrupt this circuit in TDP-43-associated disease. Stau1 haploinsufficiency in Prp -TDP-43 Q331K mice improved motor performance and open-field measures, reduced TDP-43 and gliosis, normalized neuronal, apoptotic, and autophagy markers, restored TDP-43-dependent splicing, and attenuated transcriptomic abnormalities. Screening 2′- O -methoxyethyl (MOE) gapmer ASOs identified ASO-45, which lowered STAU1 in patient-derived fibroblasts and mouse CNS. Intracerebroventricular ASO-45 improved spinal-cord and motor-cortex phenotypes, restored splicing, and attenuated cortical transcriptomic abnormalities. In independent Thy1 -TDP-43 models, ASO-45 improved molecular markers and extended survival by 9.5–15.7%. These findings show that STAU1 lowering can disrupt a self-amplifying mTOR–autophagy–stress-granule axis and nominate STAU1-directed ASOs as a disease-modifying strategy for ALS/FTD.
No takes yet. Share an insight, caveat, or question.
Spielmann et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: